The recent design of mutation-selective KRAS inhibitors has led to US Food and Drug Administration approval of two inhibitors of KRAS(G12C), sotorasib and adagrasib. A study published in Nature reports the development of a first-in-class pan-KRAS-selective inhibitor. Here we comment on the current status of KRAS-targeting approaches.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ryan, M. B. & Corcoran, R. B. Nat. Rev. Clin. Oncol. 15, 709–720 (2018).
Janne, P. A. et al. N. Engl. J. Med. 387, 120–131 (2022).
Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).
Wang, X. et al. J. Med. Chem. 65, 3123–3133 (2022).
Zhang, Z., Guiley, K. Z. & Shokat, K. M. Nat. Chem. Biol. 18, 1177–1183 (2022).
Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z. & Shokat, K. M. J. Am. Chem. Soc. 144, 15916–15921 (2022).
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Cancer Discov. 12, 924–937 (2022).
Kim, D. et al. Nature 619, 160–166 (2023).
Awad, M. M. et al. N. Engl. J. Med. 384, 2382–2393 (2021).
Tanaka, N. et al. Cancer Discov. 11, 1913–1922 (2021).
Koltun, E. S. et al. Cancer Res. 82, 3597–3597 (2022).
Ryan, M. B. et al. Cell Rep. 39, 110993 (2022).
Hunter, J. C. et al. Mol. Cancer Res. 13, 1325–1335 (2015).
Killoran, R. C. & Smith, M. J. J. Biol. Chem. 294, 9937–9948 (2019).
Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, Astellas, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Cogent Biosciences, Daiichi-Sankyo Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Natera, Navire, Nested Therapeutics, N-of-one/Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Syndax, Tango Therapeutics, Taiho and Theonys; holds equity in Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Remix Therapeutics, Revolution Medicines and Theonys; is a co-founder, equity holder and board member of Alterome Therapeutics and Sidewinder Therapeutics; and has received research funding from Asana, AstraZeneca, Invitae, Lilly, Novartis and Pfizer.
Rights and permissions
About this article
Cite this article
Corcoran, R.B. A single inhibitor for all KRAS mutations. Nat Cancer 4, 1060–1062 (2023). https://doi.org/10.1038/s43018-023-00615-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00615-x
